dc.contributor.author | Kramp, KL | |
dc.contributor.author | DeWitt, K | |
dc.contributor.author | Flora, JW | |
dc.contributor.author | Muddiman, DC | |
dc.contributor.author | Slunt, KM | |
dc.contributor.author | Houston, TA | |
dc.date.accessioned | 2017-05-03T13:55:49Z | |
dc.date.available | 2017-05-03T13:55:49Z | |
dc.date.issued | 2005 | |
dc.identifier.issn | 0040-4039 | |
dc.identifier.doi | 10.1016/j.tetlet.2004.11.112 | |
dc.identifier.uri | http://hdl.handle.net/10072/4947 | |
dc.description.abstract | The Leishmania lipophosphoglycan (LPG) is the most abundant cell surface glycoconjugate of a family of infectious protozoa. Pentamidine, a common drug used in the treatment of Leishmania infections, has been modified with boronic acids so that it might bind more selectively to the phosphodisaccharide repeating unit of the LPG. This could serve to target the drug to the protozoan surface and increase its efficacy in vivo | |
dc.description.peerreviewed | Yes | |
dc.description.publicationstatus | Yes | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | Elsevier - Pergamon | |
dc.publisher.place | Oxford, UK | |
dc.relation.ispartofstudentpublication | N | |
dc.relation.ispartofpagefrom | 695 | |
dc.relation.ispartofpageto | 698 | |
dc.relation.ispartofjournal | Tetrahedron Letters | |
dc.relation.ispartofvolume | 46 | |
dc.rights.retention | Y | |
dc.subject.fieldofresearch | Medicinal and biomolecular chemistry | |
dc.subject.fieldofresearch | Organic chemistry | |
dc.subject.fieldofresearchcode | 3404 | |
dc.subject.fieldofresearchcode | 3405 | |
dc.title | Derivatives of pentamidine designed to target the Leishmania lipophosphoglycan | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dc.type.code | C - Journal Articles | |
gro.date.issued | 2015-05-11T00:49:20Z | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Houston, Todd A. | |